# Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

> **NCT05361668** · PHASE2 · COMPLETED · sponsor: **Crinetics Pharmaceuticals Inc.** · enrollment: 36 (actual)

## Conditions studied

- Carcinoid Syndrome
- Carcinoid
- Carcinoid Tumor
- Carcinoid Tumor of Ileum
- Carcinoid Tumor of Cecum
- Carcinoid Syndrome Diarrhea
- Carcinoid Intestine Tumor
- Carcinoid Tumor of Liver
- Carcinoid Tumor of Pancreas

## Interventions

- **DRUG:** Randomized: 40 mg Paltusotine
- **DRUG:** Randomized: 80 mg Paltusotine

## Key facts

- **NCT ID:** NCT05361668
- **Lead sponsor:** Crinetics Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-22
- **Primary completion:** 2024-03-07
- **Final completion:** 2026-02-24
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361668, "Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05361668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*